Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Abdulraheem Yacoub, MD
University of Kansas School of Medicine
Study Chair - John Mascarenhas, MD
Icahn School of Medicine at Mount Sinai
Study Chair - Ruben Mesa, MD, FACP
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Study ChairKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the University of Kansas Cancer Center-Westwood
Westwood, Kansas, United States
Abdulraheem Yacoub - Icahn School of Medicine at Mount Sinai
New York, New York, United States
John Mascarenhas - Wake Forest Baptist Health Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Ruben Mesa
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 May 2026
- Primary completion
- 24 May 2030
- Completion
- 24 May 2030
- Last update posted
- 18 Mar 2026
- Registered enrollment
- 26
- Registry id
- NCT07447817
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.